EGFR Monoclonal Antibody (EGFR.1) | Invitrogen MA5-13048 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Invitrogen

other brands :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

product type :

antibody

product name :

EGFR Monoclonal Antibody (EGFR.1)

catalog :

MA5-13048

quantity :

500 µL

price :

US 496.00

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

EGFR.1

reactivity :

human, domestic horse

application :

western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, flow cytometry, immunohistochemistry - frozen section, blocking or activating experiments

citations: 35

Published Application/Species/Sample/Dilution	Reference
immunocytochemistry; human; fig s9	Perillo E, Liu Y, Huynh K, Liu C, Chou C, Hung M, et al. Deep and high-resolution three-dimensional tracking of single particles using nonlinear and multiplexed illumination. Nat Commun. 2015;6:7874 pubmed publisher
immunohistochemistry; human	Yu L, Cheng H, Yang S. Clinicopathological and extensive immunohistochemical study of a type II pleuropulmonary blastoma. Fetal Pediatr Pathol. 2014;33:1-8 pubmed publisher
immunocytochemistry; human; fig s1	Minai L, Yeheskely Hayon D, Yelin D. High levels of reactive oxygen species in gold nanoparticle-targeted cancer cells following femtosecond pulse irradiation. Sci Rep. 2013;3:2146 pubmed publisher
immunocytochemistry; human western blot; human	Oksvold M, Pedersen N, Forfang L, Smeland E. Effect of cycloheximide on epidermal growth factor receptor trafficking and signaling. FEBS Lett. 2012;586:3575-81 pubmed publisher
immunoprecipitation; human	Freeman D, McDorman K, Ogbagabriel S, Kozlosky C, Yang B, Doshi S, et al. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer. 2012;11:47 pubmed publisher
blocking or activating experiments; human	Minai L, Yeheskely Hayon D, Golan L, Bisker G, Dann E, Yelin D. Optical nanomanipulations of malignant cells: controlled cell damage and fusion. Small. 2012;8:1732-9 pubmed publisher
immunocytochemistry; human immunohistochemistry; human	Bertelsen V, Sak M, Breen K, Rødland M, Johannessen L, Traub L, et al. A chimeric pre-ubiquitinated EGF receptor is constitutively endocytosed in a clathrin-dependent, but kinase-independent manner. Traffic. 2011;12:507-20 pubmed publisher
immunocytochemistry; human; 1:100	Zeineldin R, Ning Y, Hudson L. The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2. J Histochem Cytochem. 2010;58:529-41 pubmed publisher
flow cytometry; human	Wegner C, Wegener C, Malerød L, Pedersen N, Progida C, Prodiga C, et al. Ultrastructural characterization of giant endosomes induced by GTPase-deficient Rab5. Histochem Cell Biol. 2010;133:41-55 pubmed publisher
flow cytometry; human	Red Brewer M, Choi S, Alvarado D, Moravcevic K, Pozzi A, Lemmon M, et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell. 2009;34:641-51 pubmed publisher
flow cytometry; human immunohistochemistry; human western blot; human	Al Nedawi K, Meehan B, Kerbel R, Allison A, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009;106:3794-9 pubmed publisher
flow cytometry; human	Pedersen N, Breen K, Rødland M, Haslekås C, Stang E, Madshus I. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2. Mol Cancer Res. 2009;7:275-84 pubmed publisher
immunocytochemistry; human	Barr D, Ostermeyer Fay A, Matundan R, Brown D. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells. J Cell Sci. 2008;121:3155-66 pubmed publisher
flow cytometry; human; 10,000 ug/ml	Offterdinger M, Bastiaens P. Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. Traffic. 2008;9:147-55 pubmed
immunohistochemistry; human; 1:25; tbl 3	Goldstein N, Decker D, Severson D, Schell S, Vicini F, Margolis J, et al. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer. 2007;110:1687-96 pubmed
immunocytochemistry; human	Sundelin K, Roberg K, Grenman R, Hakansson L. Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines. J Oral Pathol Med. 2007;36:177-83 pubmed
immunocytochemistry; human	Myromslien F, Grøvdal L, Raiborg C, Stenmark H, Madshus I, Stang E. Both clathrin-positive and -negative coats are involved in endosomal sorting of the EGF receptor. Exp Cell Res. 2006;312:3036-48 pubmed
immunocytochemistry; human	Johannessen L, Pedersen N, Pedersen K, Madshus I, Stang E. Activation of the epidermal growth factor (EGF) receptor induces formation of EGF receptor- and Grb2-containing clathrin-coated pits. Mol Cell Biol. 2006;26:389-401 pubmed
immunocytochemistry; human	Haslekås C, Breen K, Pedersen K, Johannessen L, Stang E, Madshus I. The inhibitory effect of ErbB2 on epidermal growth factor-induced formation of clathrin-coated pits correlates with retention of epidermal growth factor receptor-ErbB2 oligomeric complexes at the plasma membrane. Mol Biol Cell. 2005;16:5832-42 pubmed
immunocytochemistry; human	Locke M, Heywood M, Fawell S, Mackenzie I. Retention of intrinsic stem cell hierarchies in carcinoma-derived cell lines. Cancer Res. 2005;65:8944-50 pubmed
immunocytochemistry; human	Longva K, Pedersen N, Haslekås C, Stang E, Madshus I. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer. 2005;116:359-67 pubmed
immunohistochemistry; human; 1:100	Odajima T, Sasaki Y, Tanaka N, Kato Mori Y, Asanuma H, Ikeda T, et al. Abnormal beta-catenin expression in oral cancer with no gene mutation: correlation with expression of cyclin D1 and epidermal growth factor receptor, Ki-67 labeling index, and clinicopathological features. Hum Pathol. 2005;36:234-41 pubmed
immunohistochemistry; human; 1:200	Lo H, Xia W, Wei Y, Ali Seyed M, Huang S, Hung M. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65:338-48 pubmed
	Randall E, Emdal K, Laramy J, Kim M, Roos A, Calligaris D, et al. Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma. Nat Commun. 2018;9:4904 pubmed publisher
	Bright L, Goût J, Lynch M. Early stages of functional diversification in the Rab GTPase gene family revealed by genomic and localization studies in Paramecium species. Mol Biol Cell. 2017;28:1101-1110 pubmed publisher
	Truong D, Puleo J, Llave A, Mouneimne G, Kamm R, Nikkhah M. Breast Cancer Cell Invasion into a Three Dimensional Tumor-Stroma Microenvironment. Sci Rep. 2016;6:34094 pubmed publisher
	Song D, Ko G, Lee J, Lee J, Lee G, Kim H, et al. Myoferlin expression in non-small cell lung cancer: Prognostic role and correlation with VEGFR-2 expression. Oncol Lett. 2016;11:998-1006 pubmed
	Koos B, Cane G, Grannas K, LÃ¶f L, ArngÃ¥rden L, Heldin J, et al. Proximity-dependent initiation of hybridization chain reaction. Nat Commun. 2015;6:7294 pubmed publisher
	JÃ¤ger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt A, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. 2015;6:21522-32 pubmed
	Ng Y, Lee J, Supko K, Khan A, Torres S, Berwick M, et al. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014;24:207-18 pubmed publisher
	Grøvdal L, Stang E, Sorkin A, Madshus I. Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res. 2004;300:388-95 pubmed
	Witton C, Reeves J, Going J, Cooke T, Bartlett J. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-7 pubmed
	Yu X, Sharma K, Takahashi T, Iwamoto R, Mekada E. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. Mol Biol Cell. 2002;13:2547-57 pubmed
	Ge H, Gong X, Tang C. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 2002;98:357-61 pubmed
	O Bryan J, Lambert Q, Der C. The src homology 2 and phosphotyrosine binding domains of the ShcC adaptor protein function as inhibitors of mitogenic signaling by the epidermal growth factor receptor. J Biol Chem. 1998;273:20431-7 pubmed

product information

Product Type :

Antibody

Product Name :

EGFR Monoclonal Antibody (EGFR.1)

Catalog # :

MA5-13048

Quantity :

500 µL

Price :

US 496.00

Clonality :

Monoclonal

Purity :

protein A

Host :

Mouse

Reactivity :

Equine, Human

Applications :

Flow Cytometry: Assay-dependent, Immunocytochemistry: 5 µg/mL, Immunohistochemistry (Frozen): Assay-dependent, Immunoprecipitation: 2 µg/mL

Species :

Equine, Human

Clone :

EGFR.1

Isotype :

IgG2b, kappa

Storage :

4° C

Description :

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Immunogen :

A431 human epidermoid cells

Format :

Liquid

Applications w/Dilutions :

Flow Cytometry: Assay-dependent, Immunocytochemistry: 5 µg/mL, Immunohistochemistry (Frozen): Assay-dependent, Immunoprecipitation: 2 µg/mL

Aliases :

2.7.10.1; 9030024J15Rik; AI552599; avian erythroblastic leukemia viral (v-erbB) oncogene homolog; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EC 2.7.10.1; egf receptor; Egfr; EGFR-related peptide; epidermal growth factor receptor; epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian); Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); ERBB; ERBB1; ErbB-1; erb-b2 receptor tyrosine kinase 1; Errb1; Errp; HER1; kinase EGFR; mENA; NISBD2; Oncogene ERBB; PIG61; Proto-oncogene c-ErbB-1; receptor tyrosine-protein kinase erbB-1; Urogastrone; wa2; wa-2; Wa5; waved 2